Drug Approval | June 10, 2022
Sanofi Dupixent gets USFDA nod for atopic dermatitis
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Healthcare is timely and personal – and its delivery should be too
A big boost to healthcare efforts of Ayush through NARIP, CCRAS
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
Ivacaftor Tablets had estimated annual sales of USD 109 million in the US.
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif (bosutinib) at 96 weeks
Cloud-native Alissa data analysis SaaS platform empowers clinical labs and researchers to scale operations with parallel analysis of genomic data
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
The Innopack confex is a perfect platform for exhibitors to demonstrate their latest developments in the fields of pharmaceutical packaging, labelling, drug delivery device design and engineering.
Subscribe To Our Newsletter & Stay Updated
